AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Trial: NCT00294684
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Schedule and dosing of placebo following portoenterostomy in infants with biliary atresia:~Days 1-3: IV - normal saline 4 mg/kg/day, divided BID Days 4-7: PO placebo 4 mg/kg/day, divided BID Week 2: PO placebo 4 mg/kg/day, divided BID Week 3: PO placebo 2 mg/kg/day, divided BID Week 4: PO placebo 2 mg/kg/day, divided BID Week 5: PO placebo 1 mg/kg/day, once a day Week 6: PO placebo 1 mg/kg/day, once a day Week 7: PO placebo 0.8 mg/kg/day, once a day Week 8: PO placebo 0.6 mg/kg/day, once a day Week 9: PO placebo 0.4 mg/kg/day, once a day Week 10: PO placebo 0.2 mg/kg/day, once a day Week 11: PO placebo 0.1 mg/kg/day, once a day Week 12-13: PO placebo 0.1 mg/kg/day, once a day every other day Week 14: Stop
Trial: NCT03168555
Drug: chenodeoxycholic acid
RxNorm normalized name: Chenodeoxycholic acid
DrugBank: Chenodeoxycholic acid (DB06777)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 1250 mg CDCA is given with a study meal
Trial: NCT04362813
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 250 mL of 5% dextrose infused IV over 2 hours. Single dose on Day 1.
Trial: NCT03528824
Drug: Diclofenac Gel
RxNorm normalized name: diclofenac Topical Gel
DrugBank: Diclofenac (DB00586)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Daily application of diclofenac gel, 4 weeks application
Trial: NCT04144049
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Subcutaneously administered, 0.2ml per injection, at most 50 injections per treatment session.
Trial: NCT00778713
Drug: Fosinopril sodium and hydrochlorothiazide 20-12.5 mg tablets
FDA approved: no
EMA approved: no
PMDA approved: no
Trial: NCT01539811
Drug: Long course antibiotics
RxNorm normalized name: long pepper extract
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Long course (\>2 weeks) of antibiotics will be prescribed
Trial: NCT01265342
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo nebulised suspension twice a day for 10 days
Trial: NCT01938001
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo (identical matched capsule) PO daily on Days 1 to 21 every 28 days
Trial: NCT00110474
Drug: Glucosamine sulfate
RxNorm normalized name: Glucosamine Sulfate
DrugBank: Glucosamine (DB01296)
FDA approved: yes
EMA approved: no
PMDA approved: no
Trial: NCT00110474
Drug: Acetaminophen
RxNorm normalized name: Acetaminophen
DrugBank: Acetaminophen (DB00316)
FDA approved: no
EMA approved: no
PMDA approved: no
Trial: NCT04003181
Drug: Antibiotics
RxNorm normalized name: Antibiotics
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Ciprofloxacin or Rifaximin for 10 days.
Trial: NCT04003181
Drug: Bile Acid Binder
RxNorm normalized name: bile salts
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Cholestyramine or Colesevelam lifelong.
Trial: NCT05007223
Drug: Doxycycline
RxNorm normalized name: Doxycycline
DrugBank: Doxycycline (DB00254)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: 200mg/day for 28 days(Given doxycycline to patients with Hailey-Hailey disease)
Trial: NCT03644108
Drug: Mucinex® ER 600 mg
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Single dose of Mucinex® 600 mg ER Bi-Layer tablet
Trial: NCT02170038
Drug: Microgynon
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Subjects will receive 21 daily oral doses of Microgynon tablets containing 0.15 mg levonorgestrel und 0.03 mg ethinylestradiol.
Trial: NCT02170038
Drug: Noristerat(BAY86-6308)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Subjects will receive one intramuscular dose of Noristerat (oily solution for intramuscular injection) containing 200 mg norethisterone enantate.
Trial: NCT01825720
Drug: (Glucose-Insulin-Potassium)GIK group
RxNorm normalized name: Streptococcus viridans group
FDA approved: no
EMA approved: no
PMDA approved: no
Description: infusion of 0.1 IU/kg/hr of insulin and mixture of 30% dextrose water with 80 mmol/l of potassium in the rate of 0.5 ml/kg/hr through out the surgery
Trial: NCT00592670
Drug: Fluoxetine
RxNorm normalized name: Fluoxetine
DrugBank: Fluoxetine (DB00472)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: 20 mg fluoxetine orally one per day for 1 week, 40 mg fluoxetine orally once per day for one week, 80 mg Fluoxetine orally for remaining 4 weeks of treatment
Trial: NCT00592670
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 20 mg placebo pill taken orally once per day for one week, 40 mg placebo pill taken orally one per day for one week, 80 mg placebo pill taken orally once per day for remaining 4 weeks.
Trial: NCT01998399
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo 180 mg loading dose followed by 90 mg BID for 90 days.
Trial: NCT03126578
Drug: LEO 32731
RxNorm normalized name: ethanol
DrugBank: Ethanol (DB00898)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: LEO 32731 is being developed by LEO Pharma.
Trial: NCT01061320
Drug: placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: The patients were assigned to receive oral placebo every day start at five day before procedure, in the morning before procedure and 24 hr post-coronary procedure.
Trial: NCT00650182
Drug: fentanyl; naltrexone
FDA approved: no
EMA approved: no
PMDA approved: no
Trial: NCT00599235
Drug: placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 3 times daily for 7 days
Trial: NCT00154115
Drug: placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo
Trial: NCT02876679
Drug: Cyclophosphamide
RxNorm normalized name: Cyclophosphamide
DrugBank: Cyclophosphamide (DB00531)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: GVHD prophylaxis: All patients will receive post-transplant 50mg/Kg/day cyclophosphamide (day +3 and +4) AND cyclosporine-A alone in case of an HLA-sibling donor, or cyclosporine-A and mycophenolate-mofetil in case of an HLA-matched unrelated donor
Trial: NCT02876679
Drug: Conditioning regimen
RxNorm normalized name: Anacin Aspirin Regimen Pill
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 30 mg/m2/day fludarabine for 5 days (day-6 to day-2) 130 mg/m2/day IV busulfan once daily for 2 days (day -4 and -3)
Trial: NCT01711658
Drug: placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 1500 mg placebo daily by mouth or by feeding tube starting 7 days before IMRT for 7 weeks prior to and during IMRT and 3 months after completion of IMRT
Trial: NCT00719537
Drug: Placebo Oral Tablet
RxNorm normalized name: placebo ORAL TABLET
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo 1 tab Daily
Trial: NCT04347278
Drug: Patients with the treatment agains COVID19
RxNorm normalized name: The New Parent First Aid KIT
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Data will be collected from patients who receive any of the treatments included in the Technical Document. Manejo clínico del COVID-19: tratamiento médico of the Ministry of Health, and Tratamientos disponibles para el manejo de la infección respiratoria por SARS-CoV-2 of the AEMPS, either as antivirals or as treatment of the inflammatory process in patients with SARS, or others as they arise.
Trial: NCT01557504
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Matching placebo to fixed dose combination tablet of sitagliptin and metformin. Matching placebo tablets are same size, shape and color as the active product, but do not contain any markings.
Trial: NCT01641718
Drug: Tissue glue
RxNorm normalized name: tissue respiratory factor
FDA approved: no
EMA approved: no
PMDA approved: no
Description: The mesh fixation for the transabdominal preperitoneal patch plastic repair will be performed with 2 mL of tissue glue.
Trial: NCT03386552
Drug: Isifera+
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Pertubation solution of lidocaine 0.5 mg ml in Ringer-Acetate buffer
Trial: NCT03386552
Drug: Buffer
RxNorm normalized name: Buffers
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Pertubation solution of Ringer-Acetate buffer
Trial: NCT00841269
Drug: Uridine
RxNorm normalized name: Uridine
DrugBank: Uridine (DB02745)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Uridine 500 mg by mouth twice per day for 6 weeks
Trial: NCT02855138
Drug: oral isotretinoin
RxNorm normalized name: Isotretinoin
DrugBank: Isotretinoin (DB00982)
FDA approved: yes
EMA approved: no
PMDA approved: no
Trial: NCT02659475
Drug: PHEN/TPM ER (Qsymia®)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: PHEN/TPM ER (Qsymia®)
Trial: NCT05317260
Drug: Antiviral Agents
FDA approved: no
EMA approved: no
PMDA approved: no
Description: The type of antiviral agents for the individual patient was selected by physicians based on a policy to reimburse a patient's health and comorbidity.
Trial: NCT02174419
Drug: Placebo tablets BID
RxNorm normalized name: placebo Oral Tablet
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo tablets BID administered for 10 weeks
Trial: NCT01034202
Drug: Norditropin® SimpleXx®
FDA approved: no
EMA approved: no
PMDA approved: no
Description: One of two dose levels, followed by NNC126-0083, administered subcutaneously (under the skin)
Trial: NCT01034202
Drug: placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo comparator
Trial: NCT01034202
Drug: Norditropin® SimpleXx®
FDA approved: no
EMA approved: no
PMDA approved: no
Description: One of two dose levels, followed by placebo, administered subcutaneously (under the skin)
Trial: NCT03010267
Drug: Cholecaliferol
RxNorm normalized name: Cholecalciferol
DrugBank: Cholecalciferol (DB00169)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Investigational product is prescribed to all of randomized subjects
Trial: NCT03291158
Drug: Minocycline
RxNorm normalized name: Minocycline
DrugBank: Minocycline (DB01017)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Subjects will be assigned into 5 cohorts of 5 subjects each, who will receive six doses of Minocin IV every 12 hours, starting on Day 1. Each dose of Minocin IV will be administered as an IV infusion over 1 hour. Subjects will be assigned to cohort based on time of bronchoalveolar lavage.
Trial: NCT00125437
Drug: spironolactone
RxNorm normalized name: Spironolactone
DrugBank: Spironolactone (DB00421)
FDA approved: yes
EMA approved: no
PMDA approved: no
Trial: NCT01184456
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 1 capsule per day for 90 days.
Trial: NCT01635608
Drug: Acetaminophen
RxNorm normalized name: Acetaminophen
DrugBank: Acetaminophen (DB00316)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: administration of 500 mg paracetamol
Trial: NCT00953225
Drug: Placebo daily for one year
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo
Trial: NCT00092677
Drug: ezetimibe (+) simvastatin
RxNorm normalized name: ezetimibe / simvastatin
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Duration of Treatment: 4 years
Trial: NCT01090102
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Four placebo capsules once daily (1.5g/d) for the first 12 weeks, PO (by mouth).~Four mesalamine capsules once daily (1.5g/d) for another 12 weeks, PO (by mouth).
Trial: NCT02708992
Drug: Azithromycin
RxNorm normalized name: Azithromycin
DrugBank: Azithromycin (DB00207)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Trial: NCT03111342
Drug: Anesthesia
RxNorm normalized name: anesthesia tray
FDA approved: no
EMA approved: no
PMDA approved: no
Description: A 2% lidocaine without vasoconstrictor injection into the cervix
Trial: NCT04616092
Drug: FEFINJECT
RxNorm normalized name: epinephrine
DrugBank: Epinephrine (DB00668)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: FEFINJECT injection
Trial: NCT01628393
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Oral capsule taken once a day
Trial: NCT02001688
Drug: Kamada-AAT for Inhalation, 80mg
FDA approved: no
EMA approved: no
PMDA approved: no
Trial: NCT02001688
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Trial: NCT02001688
Drug: Kamada-AAT for Inhalation, 160mg
FDA approved: no
EMA approved: no
PMDA approved: no
Trial: NCT00858936
Drug: IK-1001
RxNorm normalized name: ethanol
DrugBank: Ethanol (DB00898)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: 6 escalating dose levels of 0.2, 0.5, 0.75, 1.0, 1.25, and 1.5 mg/kg/hr infusion for 6 hours
Trial: NCT00858936
Drug: Normal Saline
RxNorm normalized name: Normal Saline Flush
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 6 escalating dose levels of 0.2, 0.5, 0.75, 1.0, 1.25, and 1.5 mg/kg/hr infusion for 6 hours
Trial: NCT04231513
Drug: E2814
RxNorm normalized name: Estradiol
DrugBank: Estradiol acetate (DB13952)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: E2814, intravenous infusion.
Trial: NCT01831804
Drug: GSK1278863
FDA approved: no
EMA approved: no
PMDA approved: no
Description: White to off-white smooth ointment with unit dose strength of 0.05%w/w, 0.1%w/w, 0.5%w/w, 1.0%w/w for topical application as single or repeat doses.
Trial: NCT01831804
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: White to off-white smooth ointment for topical application as single or repeat doses.
Trial: NCT04503863
Drug: NPC-22
RxNorm normalized name: ALCOHOL 377.5 mL in 500 mL TOPICAL GEL [ANIOSGEL 85 NPC]
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Single administration of middle dose NPC-22
Trial: NCT04503863
Drug: NPC-22
RxNorm normalized name: ALCOHOL 377.5 mL in 500 mL TOPICAL GEL [ANIOSGEL 85 NPC]
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Single administration of high dose NPC-22
Trial: NCT04503863
Drug: NPC-22 Placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Single administration of NPC-22 Placebo
Trial: NCT01629628
Drug: 6 Mercaptopurine
RxNorm normalized name: 6-Mercaptopurine
DrugBank: Mercaptopurine (DB01033)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: 6MP will be administered orally starting at a dose of 6MP of 50mg/day with escalating doses every 1-2 weeks as tolerated, to a target dose of 1-1.5 mg/kg.~--------------------------------------------------------------------------------
Trial: NCT00003508
Drug: Antineoplaston therapy (Atengenal + Astugenal)
RxNorm normalized name: Monistat Simple Therapy
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Patients with advanced mesothelioma will receive Antineoplaston therapy (Atengenal + Astugenal).~The daily doses of A10 and AS2-1 are divided into six infusions, which are given at 4-hourly intervals. Each infusion starts with infusion of A10 and is immediately followed by infusion of AS2-1.hourly interEach infusion starts with infusion of A10 and is immediately followed by infusion of AS2-1.
Trial: NCT01751126
Drug: NOVA22007 ''Ciclosporin''
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Sterile, ophthalmic cationic oil-in-water emulsion containing 1 mg/ml Ciclosporin.
Trial: NCT01751126
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Sterile, drug-free, cationic ophthalmic oil-in-water emulsion containing 0 mg/ml Ciclosporin.
Trial: NCT03588091
Drug: Placebo Oral Tablet
RxNorm normalized name: placebo ORAL TABLET
FDA approved: no
EMA approved: no
PMDA approved: no
Description: placebo: 400mg orally daily;
Trial: NCT00728455
Drug: placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Dose level 1: NNC 0070-0002-0349 placebo. Subjects administered placebo will receive a subcutaneous injection. Subjects in the first 3 dose groups will receive two injections: one of randomized treatment (drug or placebo) and placebo
Trial: NCT00728455
Drug: placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Dose level 2: NNC 0070-0002-0349 placebo. Subjects administered placebo will receive a subcutaneous injection. Subjects in the first 3 dose groups will receive two injections: one of randomized treatment (drug or placebo) and placebo
Trial: NCT00728455
Drug: placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Dose level 3: NNC 0070-0002-0349 placebo. Subjects administered placebo will receive a subcutaneous injection. Subjects in the first 3 dose groups will receive two injections: one of randomized treatment (drug or placebo) and placebo
Trial: NCT00728455
Drug: placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Dose level 4: NNC 0070-0002-0349 placebo for s.c. injection
Trial: NCT00728455
Drug: placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Dose level 5: NNC 0070-0002-0349 placebo for s.c. injection
Trial: NCT03606785
Drug: placebo injection
FDA approved: no
EMA approved: no
PMDA approved: no
Description: patients will receive a placebo of 100 mL 0.9% normal saline
Trial: NCT00400374
Drug: Celecoxib
RxNorm normalized name: Celecoxib
DrugBank: Celecoxib (DB00482)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Celecoxib, 400 mg, daily for 6 months.
Trial: NCT00648791
Drug: Proscar Tablets 5 mg
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 5mg, single dose fasting
Trial: NCT02623062
Drug: Matched placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Contents of 2 sachets taken four times daily for 7 days
Trial: NCT01371604
Drug: IDX184
FDA approved: no
EMA approved: no
PMDA approved: no
Description: IDX184 50 mg tablet administered orally
Trial: NCT03492515
Drug: Platelet Concentrate
RxNorm normalized name: platelet glycoprotein VI
FDA approved: no
EMA approved: no
PMDA approved: no
Description: according to the their conditions, use if necessary
Trial: NCT03374254
Drug: Leucovorin
RxNorm normalized name: Leucovorin
DrugBank: Leucovorin (DB00650)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: 400 mg/m\^2 as IV infusion. Administered Q2W as part of mFOLFOX7 or FOLFIRI cocktail, depending upon allocation.
Trial: NCT03374254
Drug: 5-Fluorouracil [5-FU]
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 2400 mg/m\^2 over 46-48 hours as IV infusion. Administered Q2W as part of mFOLFOX7 or FOLFIRI cocktail, depending upon allocation. Dose may be de-escalated to 2000 mg/m\^2 if the standard dose of mFOLFOX7 or FOLFIRI is deemed too toxic per mTPI, based upon occurrence of DLTs.
Trial: NCT00278057
Drug: dialysisis with and without glucose in the dialysis
FDA approved: no
EMA approved: no
PMDA approved: no
Trial: NCT02308969
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Capsules containing mannitol looking identical to LSD
Trial: NCT02242812
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Trial: NCT02323412
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo tablets 1x3 for 100 days (oral intake).
Trial: NCT04435912
Drug: Hydrocortisone 200mg IV
RxNorm normalized name: Hydrocortisone
DrugBank: Hydrocortisone succinate (DB14545)
FDA approved: yes
EMA approved: yes
PMDA approved: no
Description: single dose pre-treatment given IV given at the time when the patient is attached to the cardiopulmonary bypass machine
Trial: NCT00860795
Drug: placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: placebo 25 ml daily in 2 divided doses for 10 days
Trial: NCT03494712
Drug: S 95010
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Single administration of S 95010 in healthy volunteers
Trial: NCT00495391
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: One oral placebo tablet twice daily for 52 weeks.
Trial: NCT00821561
Drug: Nexagon® vehicle
FDA approved: no
EMA approved: no
PMDA approved: no
Trial: NCT05496205
Drug: iN1011-N17
FDA approved: no
EMA approved: no
PMDA approved: no
Description: This study will be conducted in approximately 104 healthy subjects in up to 13 sequential dose cohorts. Thirteen cohorts will consist of up to 8 subjects, including 2 subjects receiving placebo and 6 subjects receiving iN1011-N17.~Each subsequent cohort will continue to be randomized and dosed until maximum exposure is attained or a stopping criterion has been reached.
Trial: NCT05496205
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Matching Placebo for each formulations
Trial: NCT03627117
Drug: Verum
RxNorm normalized name: ILLICIUM VERUM WHOLE
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Single vape of 0.25mL of CBD e-Liquid containing: 5% CBD (low-temperature extracted Cannabidiol from Cannabis sativa L., purity 99%), Glycerine (vegetable), Propylene glycol, water
Trial: NCT03627117
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Single vape of 0.25ml e-liquid La Baronne Jaune, BORDO2.
Trial: NCT01253629
Drug: AFQ056
FDA approved: no
EMA approved: no
PMDA approved: no
Description: AFQ056, was provided as hard gelatin capsules, 25mg and 100 mg oral dosage strengths, identical in appearance were used
Trial: NCT01253629
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo medication identical in appearance to active medication was provided
Trial: NCT02394600
Drug: Grastek®
FDA approved: no
EMA approved: no
PMDA approved: no
Description: one tablet daily for four months
Trial: NCT02394600
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: one tablet daily for four months
Trial: NCT03139851
Drug: Cyclophosphamide 50mg
RxNorm normalized name: CYCLOPHOSPHAMIDE 50MG TAB
DrugBank: Cyclophosphamide (DB00531)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: One tablet per day. Cyclophosphamide will continue to be administered as long as patient experiences clinical benefit in the opinion of the investigator or symptomatic deterioration attributed to disease progression as determined by the investigator after an integrated assessment of radiographic data and clinical status or withdrawal of consent.
Trial: NCT00456339
Drug: Prednisolone and amoxicillin/clavulanate
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Prednisolone 1mg/kg QD for 5 days Amoxicillin/clavulanate 45mg/Kg/d divided BID for 10 days
Trial: NCT01355809
Drug: Inhalation gas
RxNorm normalized name: INHALATION GAS
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Inhalated gas, medicinal oxygen 100% via NIV with Fi O2 0.35, one time by random, 6 minutes
Trial: NCT01664156
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no